Flash Finance

Wockhardt LimitedWOCKPHARMACorporate

Healthcare Drug Manufacturers - Specialty & Generic Latest results: Jun 2026 15 quarters of data
Consolidated Standalone
₹1,954.90
MCap ₹31,766 Cr · P/E 89.2
Wockhardt Limited — Stock analysis & AI research Wockhardt Limited — Multibagger AI analysis Wockhardt Limited — Seasonality — best & worst months Wockhardt Limited — Technical indicators & charts Wockhardt Limited — Technical setup — score, trend, support & resistance Wockhardt Limited — Live exchange announcements
📋 Stocks With Strong Quarterly Results📋 Small Cap Stocks List 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹561 Cr
Sales · Jun 2026
+35.8% YoY
₹158 Cr
Operating Profit · Jun 2026
+20.5% YoY
28.1%
OPM % · Jun 2026
-11.4% YoY
₹107 Cr
Net Profit · Jun 2026
+55.1% YoY
₹6.62
EPS · Jun 2026
+55.8% YoY

📝 Wockhardt Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Wockhardt Limited reported revenue of ₹561 crore for the quarter ended June 2026 (Q1 FY27), up 35.8% from ₹413 crore in the same quarter last year, and up 8.7% sequentially over the March 2026 quarter.

Net profit rose 55.1% year-on-year to ₹107 crore, from ₹69 crore. Earnings per share (EPS) came in at ₹6.62.

Operating profit stood at ₹158 crore — an operating margin (OPM) of 28.1%, compared with 31.7% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Wockhardt Limited posted revenue of ₹1,769 crore, a growth of 26.2% over FY25, with a net profit of ₹318 crore.

On a trailing-twelve-month (TTM) basis, revenue stands at ₹1,917 crore with a net profit of ₹356 crore.

Valuation snapshot

At the current price of ₹1,954.90, WOCKPHARMA has a market capitalisation of ₹31,766 crore and a trailing P/E of about 89.2.

Within the Drug Manufacturers - Specialty & Generic industry, it is the 19th-largest of the 31 companies we track by market value.

Shareholding pattern

As of Jun 2026, promoters held 49.08%, foreign institutional investors (FIIs) 7.22%, domestic institutional investors (DIIs) 9.24%, the government 0.02%, public shareholders 34.44% of Wockhardt Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹31,766 Cr
Current Price ?
₹1,954.9
P/E ?
89.23above ind
Industry P/E ?
35.00
P/B ?
10.30
P/S ?
16.57
P/FCF ?
-1,221.75
Enterprise Value ?
₹33,730 Cr
EV/EBITDA ?
69.41
PEG ?
1.86
Earnings Yield ?
0.9%
Dividend Yield ?
0.00%
Profitability & Returns
Sales (TTM) ?
₹1,917 Cr
OPM ?
25.3%
Profit after tax (TTM) ?
₹356 Cr
EPS (TTM) ?
₹21.91
ROCE ?
10.0%
ROE ?
11.5%
ROA ?
6.0%
Growth
Sales — latest qtr ?
₹561 Cr
PAT — latest qtr ?
₹107 Cr
YoY qtr sales growth ?
35.8%
YoY qtr profit growth ?
55.1%
Sales growth (3y) ?
18%
Sales growth (5y) ?
12%
Profit growth (3y) ?
48%
Profit growth (5y) ?
-17%
Financial Health
Debt ?
₹1,964 Cr
Debt to Equity ?
0.64
Interest Coverage ?
1.6
Current Ratio ?
N/A
Ownership
Promoter holding ?
49.08%
Change in promoter holding ?
-0.01%
Pledged percentage ?
N/A
Market
Return 3 months ?
2.9%
Return 6 months ?
40.1%

🗓️ Quarterly results (15 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 300291251260288355352370325355413410430516561 +35.8% +8.7%
Operating Profit -55-30-5-1025-4680496210613154113161158 +20.5% -1.9%
Other Income —-156-8652427116142530179033 +32.0% -63.3%
Interest 525858596159585348404144504143 +4.9% +4.9%
Depreciation 474544444345434342404645524341 -10.9% -4.7%
Profit Before Tax -55-289-115-107-74-1266-36-2240695428167107 +55.1% -35.9%
Net Profit -55-299-115-107-74-1266-36-2240695428167107 +55.1% -35.9%
EPS -3.82-20.75-7.98-7.43-5.14-8.210.39-2.34-1.402.464.253.321.7210.286.62 +55.8% -35.6%
OPM % -18.3% -10.3% -2.0% -3.8% 8.7% -13.0% 22.7% 13.2% 19.1% 29.9% 31.7% 13.2% 26.3% 31.2% 28.1% -11.4% -9.9%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹1,402 Cr ₹1,769 Cr ₹1,917 Cr +26.2%
Operating Profit ₹297 Cr ₹459 Cr ₹486 Cr +54.5%
OPM % 21.18% 25.95% 25.35% +22.5%
NPM % -0.86% 17.98% 18.57% +2190.7%
Other Income ₹58 Cr ₹162 Cr ₹170 Cr +179.3%
Depreciation ₹168 Cr ₹186 Cr ₹181 Cr +10.7%
Interest ₹199 Cr ₹176 Cr ₹178 Cr -11.6%
EBIT ₹129 Cr ₹273 Cr ₹305 Cr +111.6%
PBT ₹-12 Cr ₹318 Cr ₹356 Cr +2750.0%
Tax — ₹0 Cr — —
Net Profit ₹-12 Cr ₹318 Cr ₹356 Cr +2750.0%
EPS ₹-0.89 ₹19.57 ₹21.94 +2298.9%
Material Cost ₹249 Cr — ₹163 Cr —
Employee Cost ₹136 Cr — ₹85 Cr —
Extraordinary Items — — — —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 72778181 +0.0%
Reserves 1,6811,7192,6823,003 +12.0%
Borrowings 2,0132,1361,7961,964 +9.4%
Other Liabilities 966936849887 +4.5%
Total Liabilities 4,7324,8685,4085,935 +9.7%
Fixed Assets 1,6251,4491,2762,628 +106.0%
CWIP 8238331,260121 -90.4%
Investments 297297719709 -1.4%
Other Assets 1,9872,2892,1532,477 +15.0%
Total Assets 4,7324,8685,4085,935 +9.7%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 71188-14241 +1821.4%
Cash from Investing Activity -3-75-900-193 +78.6%
Cash from Financing Activity -236346486-7 -101.4%
Net Cash Flow -168459-42841 +109.6%
Free Cash Flow 63100-508-26 +94.9%
CFO/OP 109%-522%-14%47% +435.7%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 188179159178 +11.9%
Inventory Days 330254357469 +31.4%
Days Payable 507459398442 +11.1%
Cash Conversion Cycle 11-26117204 +74.4%
Working Capital Days -404-223-7178 +2642.9%
ROCE % -1%-4%4%10% +150.0%

👥 Shareholding (latest 5 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 % Chg
Promoters 49.09%49.09%49.09%49.09%49.08% -0.0%
FIIs 7.29%7.10%7.00%7.09%7.22% +1.8%
DIIs 11.00%11.00%10.55%10.96%9.24% -15.7%
Government 0.02%0.02%0.02%0.04%0.02% -50.0%
Public 32.60%32.79%33.36%32.84%34.44% +4.9%
No. of Shareholders 1,46,9181,37,9461,42,2741,39,0161,66,518 +19.8%

⚖️ Peer comparison

Industry: Drug Manufacturers - Specialty & Generic · top 25 of 31 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 SUNPHARMA Sun Pharmaceutical ₹1,840.00 441,478 36.5 59,911 12,104 29.8% 20.2% 11.2% 5.1% 10.5% 27.0%
2 DIVISLAB Divi's Laboratories ₹9,235.00 245,160 83.8 11,230 2,925 35.3% 26.0% 12.8% 16.7% 27.8% 65.5%
3 TORNTPHARM Torrent Pharmaceuticals ₹4,931.00 187,559 87.1 15,723 2,156 33.0% 13.7% 21.4% 11.9% 54.8% 3.3%
4 ZYDUSLIFE Zydus Lifesciences ₹1,162.20 115,930 23.2 27,148 5,070 31.2% 18.7% 16.8% 12.0% 16.2% 14.5%
5 CIPLA Cipla ₹1,366.00 110,353 32.7 28,324 3,356 18.7% 11.8% 2.2% -26.7% 2.3% -39.2%
6 LAURUSLABS Laurus Labs ₹1,969.00 106,387 97.2 7,270 1,090 28.0% 15.0% 22.7% 147.9% 29.1% 123.9%
7 DRREDDY Dr. Reddy's ₹1,165.50 97,085 29.3 28,704 3,273 15.3% 11.4% -10.4% -25.8% -5.6% -69.2%
8 AUROPHARMA Aurobindo Pharma ₹1,679.80 96,652 26.2 34,935 3,711 20.3% 10.6% 6.1% 0.6% 16.3% 25.2%
9 LUPIN Lupin ₹2,095.00 95,797 17.9 27,958 5,356 31.5% 19.2% 23.1% 62.0% 31.9% 87.8%
10 MANKIND Mankind Pharma ₹2,280.00 94,174 46.1 14,738 2,067 26.0% 14.0% 16.3% -3.7% 12.9% 29.1%
11 GLENMARK Glenmark Pharmaceuticals ₹2,419.20 68,276 38.0 17,737 1,797 27.0% 10.1% -61.2% -67.4% 23.1% 927.9%
12 ALKEM Alkem Laboratories ₹5,243.50 62,694 29.1 15,081 2,187 20.1% 14.5% 13.5% 7.6% 10.9% -21.6%
13 ABBOTINDIA Abbott India ₹25,860.00 54,951 34.0 7,005 1,615 28.1% 23.1% 8.1% 9.7% 4.4% 17.2%
14 IPCALAB Ipca Laboratories ₹1,964.20 49,833 38.0 10,125 1,379 22.0% 13.6% 7.9% 55.0% 20.8% 82.2%
15 GLAND Gland Pharma ₹2,935.90 48,433 47.1 6,431 1,028 25.3% 16.0% -64.7% -48.4% 22.3% 96.7%
16 AJANTPHARM Ajanta Pharma ₹3,398.90 42,472 37.4 5,777 1,135 25.4% 19.7% 17.3% 14.8% 24.8% 30.9%
17 JBCHEPHARM J. B. ₹2,416.10 38,793 53.4 4,148 709 26.7% 17.1% 5.9% 7.5% -4.8% -30.7%
18 EMCURE EMCURE PHARMACEUTICALS ₹1,975.10 37,470 37.0 9,684 1,019 20.4% 10.5% 16.6% 33.1% 22.8% 36.0%
19 WOCKPHARMA Wockhardt ₹2,021.50 32,848 92.5 3,133 353 19.9% 11.3% -2.3% 342.1% 25.9% 199.1%
20 NEULANDLAB Neuland Laboratories ₹23,455.00 30,093 82.7 2,023 365 28.4% 18.0% 37.0% 40.2% 136.3% 666.0%
21 PPLPHARMA Piramal Pharma ₹211.50 28,024 113.5 9,206 247 11.0% 2.7% -3.1% -37.9% 17.4% -161.3%
22 GRANULES Granules India ₹885.60 21,945 32.8 5,633 663 22.7% 11.8% 19.7% 18.8% 22.0% 59.3%
23 CAPLIPOINT Caplin Point ₹2,752.60 20,923 31.4 2,287 678 34.8% 29.7% 12.9% 20.2% 19.6% 18.8%
24 ERIS Eris Lifesciences ₹1,358.00 18,820 29.0 3,230 666 35.2% 20.6% 8.2% 72.6% 13.0% 14.6%
25 ASTRAZEN AstraZeneca Pharma ₹6,755.00 16,888 99.6 2,432 170 9.4% 7.0% 32.7% 62.1% 29.7% -32.1%
❓ Frequently asked questions
What was Wockhardt Limited's revenue in Q1 FY27?
Wockhardt Limited reported revenue of ₹561 crore for the quarter ended June 2026 (Q1 FY27), up 35.8% from ₹413 crore in the same quarter last year, and up 8.7% sequentially over the March 2026 quarter.
What was Wockhardt Limited's net profit in Q1 FY27?
Net profit rose 55.1% year-on-year to ₹107 crore, from ₹69 crore. Earnings per share (EPS) came in at ₹6.62.
What is WOCKPHARMA's market capitalisation and P/E ratio?
At the current price of ₹1,954.90, WOCKPHARMA has a market capitalisation of ₹31,766 crore and a trailing P/E of about 89.2.
Who owns Wockhardt Limited? (shareholding pattern)
As of Jun 2026, promoters held 49.08%, foreign institutional investors (FIIs) 7.22%, domestic institutional investors (DIIs) 9.24%, the government 0.02%, public shareholders 34.44% of Wockhardt Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI